Abstract
<p>Supplementary Figure 1. Activation of the CDK4/6 axis in human intrahepatic cholangiocarcinoma (ICC) specimens. Supplementary Figure 2. Levels of Rb1, CDK4, CDK6, E2F1, and Cyclin E1 mRNA in human intrahepatic cholangiocarcinoma (ICC) from The Cancer Genome Atlas (TCGA) and National Cancer Institute (NCI) datasets. Supplementary Figure 3: Effect of Palbociclib on ICC cell growth. Supplementary Figure 4: Effect of Palbociclib on the levels of putative target proteins in human ICC cell lines. Supplementary Figure 5. Inhibition of CyclinD1 (CCND1) expression enhances tumor cell growth suppressor capacity of Palbobiclib. Supplementary Figure 6. Correlation analysis of Retinoblastoma (Rb) expression and the growth inhibitory effects of Palbociclib. Supplementary Figure 7. Palbociclib inhibits proliferation of ICC cell lines in colony formation assays. Supplementary Figure 8. Retinoblastoma-dependent cell growth inhibition effect of long-term Palbociclib treatment in ICC cells. Supplementary Figure 9. Effect of combined Palbociclib/MLN0128 treatment on cell proliferation. Supplementary Figure 10. Synergistic effect of Palbociclib/MLN0128 combination in ICC cell lines. Supplementary Figure 11. Effect of combined Palbociclib/MLN0128 administration on cell cycle of ICC cell lines. Supplementary Figure 12. Effect of Palbociclib/MLN0128 on putative target proteins in intrahepatic cholangiocarcinoma (ICC) cell lines. Supplementary Figure 13. Overview of the apoptosis rate in ICC lesions from AKT/YapS127A mice subjected to the various treatment regimens. Supplementary Figure 14. Effect of Palbociclib/MLN0128 treatment on putative target proteins in AKT/YapS127A mice. Supplementary Table 1: Clinicopathological features of intrahepatic cholangiocarcinoma (ICC) patients Supplementary Table 2: Western blotting antibody information</p>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.